The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: A systematic review and economic evaluation

Health Technology Assessment

Volumn 11, Issue 18, 2007, Pages

  Garside, R ^a   Pitt, M ^a   Anderson, R ^a   Mealing, S ^a   Roome, C ^b   Snaith, A ^a   D'Souza, R ^b   Welch, K ^c   Stein, K ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM ION; CALCIUM SENSING RECEPTOR; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; VITAMIN D; NAPHTHALENE DERIVATIVE;

ABDOMINAL PAIN; ANOREXIA; ASTHENIA; BIBLIOGRAPHIC DATABASE; BLOOD PRESSURE; BONE DENSITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA EXTRACTION; DIARRHEA; DIZZINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPEPSIA; ECONOMIC EVALUATION; FATIGUE; FOLLOW UP; HEALTH CARE COST; HEART ARREST; HEMODIALYSIS; HIP FRACTURE; HOSPITALIZATION; HUMAN; HYPOCALCEMIA; HYPOTENSION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEG FRACTURE; MEDICAL RESEARCH; META ANALYSIS; MORTALITY; MYALGIA; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PARATHYROIDECTOMY; PERITONEAL DIALYSIS; PNEUMONIA; PROBABILITY; PROSPECTIVE PAYMENT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SEIZURE; SENSITIVITY ANALYSIS; SEPSIS; SIDE EFFECT; SIMULATION; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG EFFECT; ECONOMICS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; STATISTICAL MODEL;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHATES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CALCIUM-SENSING; RENAL DIALYSIS; VITAMIN D;

EID: 85046912332     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11180     Document Type: Review

References (108)

1. Renal Association. Chronic kidney disease in adults: UK guidelines for identification, management and referral. London: Renal Association; 2005.
2. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2003; 42(Suppl 3):S1-170.
3. Joint Specialty Committee on Renal Disease. Chronic kidney disease in adults: UK guidelines for identification, management and referral of adults. London: Renal Association and Royal College of Physicians; 2005.
4. Coladonato JA, Ritz E. Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Adv Ren Replace Ther 2002;9:193-9.
5. de Francisco ALM. Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther 2004;26: 1976-93.
6. Department of Health Renal NSF Team. The National Service Framework for Renal Services. Part One: Dialysis and transplantation. London: Department of Health; 2004.
7. Sexton J, Vincent M. Remedying calcium and phosphate problems in chronic kidney disease. Pharmaceutical Journal 2005;274:561-4.
8. Drueke TB, Ritz E. Skeletal disorders, In: Davison A, Cameron JS, Grunfeld J-P, Porticelli C, Ritz E, Winearls CG, et al., editors. Oxford textbook of clinical nephrology. 3rd ed. Oxford: Oxford University Press; 2005. pp. 1-71.
9. Drueke TB. The place of calcium and calcimimetics in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant 2001; 16(Suppl 6):15-17.
10. Renal Association. Treatment of adults and children with renal failure - standards and audit measures. 3rd ed. London: Renal Association; 2002.
11. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
12. Ehrlich JE, Rumberger JA. Detection and clinical management of cardiovascular calcification in ESRD: a review. Dialysis and Transplantation 2004;33:306-13.
13. Ansell D, Feest T, Byrne C, Ahmad A, Burden R, Burton C, et al., editors. UK Renal Registry - the Sixth Annual Report. London: Renal Association; 2003.
14. Cannata Andia JB. Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000;320:81-4.
15. Khan I, Catto GRD, Edward N, MacLeod AM. Chronic renal failure; factors influencing nephrology referral. QJM 1994;87:559-64.
16. Ansell D, Feest T, Ahmad A, Rao R. UK Renal Registry Seventh Annual Report. London: Renal Association; 2004.
17. Feest TG, Mistry CD, Grimes DS, Mallick NP. Incidence of advanced chronic renal failure and the need for end-stage renal replacement therapy. BMJ 1990; 301:987-90.
18. Department of Health Renal NSF Team. National Service Framework for Renal Services. Part Two: Chronic kidney disease, acute renal failure end of life care. London: Department of Health; 2005.
19. Biock GA, Klassen P, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
20. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephhrol 1998;11:239-45.
21. Chandna SM, Schulz J, Lawrence C, Greenwood RN, Farrington K. Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. BMJ 1999; 318:217-23.
22. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458-82.
23. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-83.
24. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft F. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
25. McCullough PA, Soman S. Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor? Kidney Int 2004;66:S18-24.
26. Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol 2004;17:405-10.
27. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002;288:3014-8.
28. Taal MW, Masud T, Green D, Cassidy MJD. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999; 14:1922-8.
29. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143(3): 174-83.
30. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. American Journal of managed care 2003;9:155-71.
31. Weatherall D, Benz EJ, Warrell DA, Weatherall DJ, Cox TM, Firth JD, editors. Oxford textbook of medicine. 4th ed. Oxford: Oxford University Press; 2003.
32. Quarles LD. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int 2005;68:S24-8.
33. Cozzolino MF, Gallieni MF, Corsi CF, Bastagli AF, Brancaccio D. Management of calcium refilling post-parathyroidectomy in end-stage renal disease. J Nephrol 2004;17:3-8.
34. Koonsman M, Hughes K, Dickerman R, Brinker K, Dunn E. Parathyroidectomy in chronic renal failure. Am J Surg 1994;168:631-5.
35. Chow KM, Szeto CC, Kum LC, Kwan BC, Fung TM, Wong TY, et al. Improved health-related quality of life and left ventricular hypertrophy among dialysis patients treated with parathyroidectomy. J Nephrol 2003;16:878-85.
36. Chou FF, Chen JB, Lee CH, Chen SH, Sheen-Chen SM. Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg 2001; 136:1064-8.
37. Elder G. Parathyroidectomy in the calcimimetic era. Nephrology 2005;10:511-5.
38. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67:1179-87.
39. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34-8.
40. Chow FY, Briganti EM, Kerr PG, Chadban SJ, Zimmet PZ, Atkins RC. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis 2003; 41:596-604.
41. Cagney KA, Wu AW, Fink NE, Jenckes MW, Meyer KB, Bass EB, et al. Formal literature review of quality-of-life instruments used in end-stage renal disease. Am J Kidney Dis 2000;36:327-36.
42. Moreno F, Lopez Gomez JM, Sanz-Guajardo D, Jofre R, Valderrabano F. Quality of life in dialysis patients. A Spanish multicentre study. Nephrol Dial Transplant 1996;11 (Suppl 2):125-9.
43. Rebolio P, Ortega F. New trends on health related quality of life assessment in end-stage renal disease patients. Int Urol Nephrol 2002;33:195-202.
44. Churchill DN, Morgan J, Torrance GW. Quality of life in end stage renal disease. Perit Dial Int 1984;4:20-3.
45. Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987;10:14-20.
46. Churchill DN, Wallace JE, Ludwin D, Beecroft ML, Taylor DW. A comparison of evaluative indices of quality of life and cognitive function in hemodialysis patients. Control Clin Trials 1991; 12(4 Suppl):159-67S.
47. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32.
48. de Wit GA, Merkus MP, Krediet RT, de Charro FT. Health profiles and health preferences of dialysis patients. Nephrol Dial Transplant 2002;17:86-92.
49. Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992; 45:505-12.
50. Molzahn AE, Northcott HC, Hayduk L. Quality of life of patients with end stage renal disease: a structural equation model. Qual Life Res 1996;5:426-32.
51. Devine EB, Smith KL, Stehman-Breen C, Patrick DL. Health-related quality of life assessment in chronic kidney disease. Expert Review of Pharmacoeconomics and Outcomes Research 2003;3:89-100.
52. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC. The association between mental health, physical function, and hemodialysis mortality. Kidney Int 2003;63: 1843-51.
53. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, et al. Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003;64:1903-10.
54. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis 2001;38:443-64.
55. Davison SN. Quality end-of-life care in dialysis units. Semin Dial 2002;15:41-4.
56. Kurella M, Suri RS, Chertow GM. Frequent hemodialysis and psychosocial function. Semin Dial 2005; 18:132-6.
57. Kutner NG. Quality of life and daily hemodialysis. Semin Dial 2004;17:92-8.
58. Heidenheim AP, Kooistra MP, Lindsay RM. Quality of life. Contrib Nephrol 2004;145:99-105.
59. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 2003;64:1004-11.
60. Mingardi G, Cornalba L, Cortinovis E, Ruggiata R, Mosconi P, Apolone G. Health-related quality of life in dialysis patients. A report from an Italian study using the SF-36 Health Survey. Nephrol Dial Transplant 1999;14:1503-10.
61. Lew SQ, Piraino B. Quality of life and psychological issues in peritoneal dialysis patients. Semin Dial 2005;18:119-23.
62. Stefanovic V, Milojkovic M. Effects of physical exercise in patients with end stage renal failure, on dialysis and renal transplantation: current status and recommendations. Int J Artif Organs 2005; 28:8-15.
63. British Medicai Association, Royal Pharmaceutical Society of Great Britain. British National Formulary No. 50. London: Pharmaceutical Press; 2005. p. 1644.
64. Byrnes CA, Shepler BM. Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis. Pharmacotherapy 2005;25:709-16.
65. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness. 2nd ed. York: NHS Centre for Reviews and Dissemination; 2001.
66. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7.
67. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58:436-45.
68. Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004;44:1070-6.
69. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24.
70. Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
71. Cunningham J, Danese MD, Olson KA, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture, and health related quality of life in secondary. hyperparathryoidism. Kidney Int 2005;68: 1793-800.
72. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63:248-54.
73. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCI. Kidney Int 2005;67:760-71.
74. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83.
75. Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-7.
76. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, et al. Long term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCI. Nephrol Dial Transplant 2005; 20:2186-93.
77. Centre for Drug Evaluation and Research, FDA. Cinacalcet medical review. 2005. URL: http://www.fda.gov/cder/foi/nda/2004/2l-688_Sensipar.htm. Accessed 2 December 2005.
78. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 2000;11:330-4.
79. Department of Health. Reference costs 2004. London: Department of Health; 2005.
80. Brouwer W, Rutten F, Koopmanschapp M. Costing in economic evaluations. In Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2005. pp. 68-93.
81. Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost-effectiveness analysis. In Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. pp. 25-53.
82. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770-9.
83. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805.
84. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 2004;44:672-9.
85. Trespalacios FC, Taylor AJ, Agodoa LY, Bakris GL, Abbott KC. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003;41:1267-77.
86. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29:517-22.
87. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M. Treatment of established osteoporosis: a systematic peview and cost-utility analysis. Health Technol Assess 2002;6(29).
88. Kim HC, Dylan M, Griffiths R, Stehman-Breen C, Dubois R, Danese M, et al. Association of elevated parathyroid hormone (PTH) and calcium with risk of hip, vertebral or pelvic fracture in hemodialysis patients [abstract]. 41st European Renal Association-European Transplant Association Congress; 15-18 May 2004.
89. Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of osteoporosis. Health Technol Assess 2005; 9(22).
90. Jofre R, Eopez-Gomez JM, Menargues J, Polo JR, Guinsburg M, Villaverde T, et al. Parathyroidectomy: whom and when? Kidney Int Suppl 2003;63:S97-100.
91. Kim HC, Cheigh JS, David DS, Stubenbord W, Sullivan J, Rubin AL, et al. Long term results of subtotal parathyroidectomy in patients with end-stage renal disease. Am Surg 1994;60:641-9.
92. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SE, Jadav PR, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004;66:2010-6.
93. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
94. Nease RF, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic heart disease team. JAMA 1995;273:1185-90.
95. Martin AJ, Glasziou PP, Situes RJ. A cardiovascular extension of the Health Measurement Questionnaire. J Epidemiol Community Health 1999;53:548-57.
96. Harvard Centre for Risk Analysis. Preference weights 1998-2001. The Cost-Effectiveness Analysis Registry. 2006. URL: http://www.hsph.harvard.edu/cearegistry/data/ phaseIIpreferenceweights.pdf. Accessed 2 December 2005.
97. Brazier JE, Green C, Kanis JA, Committee of Scientific Advisors International Osteoporosis Foundation. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis Int 2002;13:768-76.
98. Singer B, McLaughlin G, Robinson C, Christie J. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg 1998;80B:243-8.
99. National Institute for Clinical Excellence. Guide to the methods of technology appraisal 17. London: National Institute for Clinical Excellence; 2004.
100. Mowatt G, Vale L, Perez J, Wyness L, Fraser C, Macleod A, et al. Systematic review of the effectiveness and cost-effectiveness, and economic evaluation, of home versus hospital or satellite unit haemodialysis for people with end-stage renal failure. Health Technol Assess 2003;7(2).
101. UK Medicines Information. New medicines profile: cinacalcet. Liverpool: UK Medicines Information Service; 2005.
102. Davison A, Cameron JS, Grunfeld J-P, Ponticelli C, Ritz E, Winearls C, et al. The Oxford textbook of clinical nephrology. 3rd ed. Oxford: Oxford University Press; 2005.
103. Foley. RN, Parfrey P. Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239-45.
104. Dotsch J, Plank C, Bosch B, Dorr HG, Rascher W. Endocrine disorders with chronic renal insufficiency. Padiatrische Praxis 2002; 61:435-46.
105. Eknoyan G, Levin A, Levin N. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):1-201.
106. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria, Int J Technol Assess Health Care 2005;21:240-54.
107. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health 2003; 6:9-17.
108. MacLeod A, Grant A, Donaldson C, Khan I, Campbell A, Daly C, et al. Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. Health Technol Assess 1998;2(5).